Skip to main content

The post-operative analgesic efficacy and tolerability of lumiracoxib compared with placebo and naproxen after total knee or hip arthroplasty

Buy Article:

$43.00 plus tax (Refund Policy)


Lumiracoxib is a novel selective cyclooxygenase-2 (COX-2) inhibitor in development for the treatment of chronic and acute pain. Methods: 

This randomized, double-blind multicentre study enrolled 180 patients (aged 18–80 years) with moderate-to-severe pain (≥2 on a 4-point categorical scale) within 48 h of unilateral total knee or total hip arthroplasty. Patients were randomized to receive lumiracoxib 400 mg once daily (n = 60), placebo (n = 60) or naproxen 500 mg twice daily (n = 60). The study consisted of a 12-h single-dose phase followed by a multiple-dose phase (up to 96 h or until discontinuation). The primary efficacy measure was the summed (time-weighted) pain intensity difference over 0–8 h after the first dose (SPID-8). Results: 

Lumiracoxib and naproxen were comparable and both treatments were superior to placebo for the primary efficacy measure, SPID-8. Both treatments were generally similar and also superior to placebo for the secondary efficacy measures during both the single- and multiple-dose phases for up to 96 h. Both active treatments were well tolerated. Conclusion: 

Lumiracoxib is an effective alternative to traditional non-selective non-steroidal anti-inflammatory drugs (NSAIDs) for the treatment of post-operative pain.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: COX-2 inhibitor; arthroplasty; lumiracoxib; naproxen; post-operative pain; selective cyclooxygenase-2 inhibitor

Document Type: Research Article

Affiliations: 1: Toronto Western Hospital, University Health Network, Toronto, ON, 2: Chronic Pain Center, Calgary Health Region, Calgary, AB, Canada, 3: Capstone Clinical Trials Inc., 4: Alabama Orthopedic Center, Capstone Clinical Trials Inc., Birmingham, AL, and 5: Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA

Publication date: 2005-11-01

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more